共 53 条
[1]
Bourne RR(2014)Prevalence and causes of vision loss in highincome countries and in Eastern and Central Europe: 1990- 2010 Br J Ophthalmol 98 629-638
[2]
Jonas JB(2016)Aflibercept for neovascular age-related macular degeneration Cochrane Database Syst Rev 2 CD011346-2548
[3]
Flaxman SR(2012)Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2537-343
[4]
Keeffe J(2016)First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration Ophthalmol 123 337-201
[5]
Leasher J(2014)Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 193-1645
[6]
Naidoo K(2016)Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration Br J Ophthalmol 100 1640-2503
[7]
Sarwar S(2015)Scheduled versus Pro Re Nata Dosing in the VIEW Trials Ophthalmology 122 2497-65.e5
[8]
Clearfield E(2009)Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study Ophthalmology 116 57-1398
[9]
Soliman MK(2012)Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results Ophthalmology 119 1388-1908
[10]
Sadiq MA(2011)Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 1897-undefined